Alpha-1-antitrypsin deficiency is associated with type 2 diabetes [71], and therapy with alpha-1-antitrypsin is already being tested as a treatment strategy for type 1 diabetes [72]. This evidence concerns the gene SERPINA1 and type 2 diabetes mellitus.